AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29912763 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 510
Study 29912763 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 510
Study 29171140 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-Alum (20 μg, 2 injections, 30 days apart)
Number of subjects: 50
Study 29171140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25119067 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Parent Information and Support (OPIS) application
Number of subjects: 20
Study 25119067 — intervention group
Group type: COMPARATOR
Intervention: Control group without access to OPIS
Number of subjects: 20
Study 25265549 — intervention group
Group type: EXPERIMENTAL
Intervention: School‐based intervention with added parent training component
Number of subjects: 52
Study 25265549 — intervention group
Group type: COMPARATOR
Intervention: School‐based program focused solely on intervening with the adolescent (no parental involvement)
Number of subjects: 52
Study 22834281 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (20% solution N(2)‐L‐alanine‐L‐glutamine, 'Dipeptiven' Fresenius Kabi, Germany); 0.4 g/kg/day
Number of subjects: 50
Study 22834281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl solution)
Number of subjects: 50
Study 20819489 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy (CRT)
Number of subjects: 158
Study 20819489 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (S)
Number of subjects: 158
Study 17932240 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry (TP)
Number of subjects: 38
Study 17932240 — intervention group
Group type: COMPARATOR
Intervention: Same Room (SR)
Number of subjects: 38
Study 16223396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg once daily
Number of subjects: 180
Study 16223396 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily
Number of subjects: 180
Study 16223396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 11870934 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 100 mg only (G1)
Number of subjects: 191
Study 11870934 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin infusion followed by 6 months of oral anticoagulation with coumadin (G2)
Number of subjects: 191
Study 10563540 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole od
Number of subjects: 12
Study 10563540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole od
Number of subjects: 12
Study 10563540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7569589 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (started as early as 6 hours postoperatively)
Number of subjects: 100
Study 7569589 — intervention group
Group type: COMPARATOR
Intervention: Oral feeding forbidden until spontaneous restoration of intestinal function
Number of subjects: 100
Study 1329919 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg
Number of subjects: 129
Study 1329919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 6377801 — intervention group
Group type: EXPERIMENTAL
Intervention: progabide (24.3 mg/kg daily for 2 weeks)
Number of subjects: 16
Study 6377801 — intervention group
Group type: EXPERIMENTAL
Intervention: progabide
Number of subjects: 16
Study 30747254 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg once per day)
Number of subjects: 54
Study 30747254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29562763 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Traveller (VT) intervention
Number of subjects: 219
Study 29562763 — intervention group
Group type: COMPARATOR
Intervention: Control (COM) group
Number of subjects: 219
Study 27060535 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapeutic mild hypercapnia (TTMH) (PaCO2 50-55mmHg)
Number of subjects: 86
Study 27060535 — intervention group
Group type: COMPARATOR
Intervention: Targeted normocapnia (TN) (PaCO2 35-45mmHg)
Number of subjects: 86
Study 27060535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 86
Study 24284515 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravesical ureteroneocystostomy
Number of subjects: 200
Study 24284515 — intervention group
Group type: COMPARATOR
Intervention: Intravesical ureteroneocystostomy
Number of subjects: 200
Study 22149445 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (0.5 ng kg(-1) min(-1))
Number of subjects: 48
Study 22149445 — intervention group
Group type: COMPARATOR
Intervention: Control (ICP-targeted therapy without prostacyclin)
Number of subjects: 48
Study 20172539 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy
Number of subjects: 752
Study 17636186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity VKA treatment (target INR 2.5) plus aspirin (100 mg/day) for the first six months (Group A)
Number of subjects: 198
Study 17636186 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity VKA treatment (target INR 3.7) (Group B)
Number of subjects: 198
Study 15662502 — intervention group
Group type: EXPERIMENTAL
Intervention: CF 540 cutoff filter
Number of subjects: 22
Study 15662502 — intervention group
Group type: EXPERIMENTAL
Intervention: CF 580 cutoff filter
Number of subjects: 22
Study 12005179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates
Number of subjects: 27
Study 10191743 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaction-grafting with demineralized bone matrix (DBM)
Number of subjects: 25
Study 10191743 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaction-grafting with fresh cancellous bone graft
Number of subjects: 25
Study 10191743 — intervention group
Group type: COMPARATOR
Intervention: Non-grafted controls
Number of subjects: 25
Study 8678266 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4‐6 mg/kg i.v., halothane 0.8‐1.5%, N2O‐‐O2 2:1, no opioids, droperidol 75 micrograms/kg i.v. (Group 1)
Number of subjects: 90
Study 8678266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2‐3 mg/kg i.v., propofol 6‐9 mg/kg.h, alfentanil 30 micrograms/kg.h, N2O‐O2 2:1, no antiemetics (Group 2)
Number of subjects: 90
Study 8678266 — intervention group
Group type: EXPERIMENTAL
Intervention: Similar to Group 2, but ventilation with air and O2 2:1 (Group 3)
Number of subjects: 90
Study 2354096 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium after sub-paralysing dose of tubocurarine (0.05 mg kg-1)
Number of subjects: 21
Study 2354096 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium after paralysing dose of atracurium (0.5 mg kg-1)
Number of subjects: 21
Study 2354096 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium alone (saline control)
Number of subjects: 21
Study 2354096 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg kg-1)
Number of subjects: 21
Study 2354096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (0.05 mg kg-1)
Number of subjects: 21
Study 2354096 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 21
Study 361313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 56
Study 361313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30658228 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous and arterial devices
Number of subjects: 7669
Study 30658228 — intervention group
Group type: EXPERIMENTAL
Intervention: Central devices
Number of subjects: 7669
Study 30658228 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial catheters
Number of subjects: 7669
Study 30658228 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial insertion
Number of subjects: 7669
Study 30658228 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilic insertion
Number of subjects: 7669
Study 30658228 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor skin integrity
Number of subjects: 7669
Study 28719609 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 46
Study 28719609 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 46
Study 25776116 — intervention group
Group type: EXPERIMENTAL
Intervention: RPMS
Number of subjects: 18
Study 25776116 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study 23347435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cabergoline treatment (weekly increase by 1 mg per week followed by 4 weekly escalation)
Number of subjects: 38
Study 23347435 — intervention group
Group type: COMPARATOR
Intervention: Conventional cabergoline treatment (4 weekly escalation by 0.5 mg per week)
Number of subjects: 38
Study 21334655 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg alone
Number of subjects: 1505
Study 21334655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1505
Study 19210150 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan Medoxomil (AML/OM) 10/40 mg
Number of subjects: 0
Study 19210150 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan (AML/VAL) 10/320 mg
Number of subjects: 0
Study 19210150 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (AML)
Number of subjects: 0
Study 19210150 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (VAL)
Number of subjects: 0
Study 19210150 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan Medoxomil (OM)
Number of subjects: 0
Study 16729783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide with salbutamol
Number of subjects: 74
Study 16729783 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol alone (control)
Number of subjects: 74
Study 15180672 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-modeling regression (SEMOR)
Number of subjects: 0
Study 15180672 — intervention group
Group type: EXPERIMENTAL
Intervention: Time warping procedures
Number of subjects: 0
Study 11883126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilumen venous catheters
Number of subjects: 100
Study 9215826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with methotrexate (30 mg/m2 on days 1, 15, and 22), vinblastine (3 mg/m2 on days 2, 15, and 22), doxorubicin (30 mg/m2 on day 2), and cisplatin (70 mg/m2 on day 2)
Number of subjects: 255
Study 9215826 — intervention group
Group type: COMPARATOR
Intervention: Single‐agent cisplatin (70 mg/m2 on day 1)
Number of subjects: 255
Study 8481018 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir suppressive therapy (400 mg twice daily)
Number of subjects: 1100
Study 3436489 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training for up to 2 years
Number of subjects: 8
Study 3436489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 8
Study 3436489 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 8
Study 29667217 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive PSA test
Number of subjects: 0
Study 29667217 — intervention group
Group type: EXPERIMENTAL
Intervention: False-positive digital rectal exam (DRE)
Number of subjects: 0
Study 29667217 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy follow-up
Number of subjects: 0
Study 29667217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor characteristics
Number of subjects: 0
Study 29667217 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence and mortality rates
Number of subjects: 0
Study 26849263 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Well, Work Well workplace intervention
Number of subjects: 0
Study 25895964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene and dietary counseling
Number of subjects: 140
Study 25895964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene and fluoride varnish application at 4, 8, and 12 months
Number of subjects: 140
Study 25895964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene and tooth mousse applied by parents twice a day for 12 months
Number of subjects: 140
Study 25895964 — intervention group
Group type: COMPARATOR
Intervention: No preventive intervention (control group)
Number of subjects: 140
Study 23086138 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 6.25 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 12.5 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 25 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 50 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 100 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-875 200 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 mg
Number of subjects: 396
Study 23086138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 20507968 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased end-expiratory lung volume (EELV)
Number of subjects: 15
Study 20507968 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased genioglossus (GG) activity
Number of subjects: 15
Study 20507968 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased EELV and increased GG
Number of subjects: 15
Study 20507968 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study 18669462 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (600 mg/m2/dose) administered as a bolus immediately before and 3 hours into the cisplatin infusion
Number of subjects: 62
Study 18669462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 62
Study 15815566 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic educational intervention
Number of subjects: 0
Study 15815566 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered Nurses (RNs)
Number of subjects: 0
Study 15815566 — intervention group
Group type: COMPARATOR
Intervention: Non-Registered Nurses (non-RNs)
Number of subjects: 0
Study 14607206 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine SR (1.5 mg BID)
Number of subjects: 1934
Study 14607206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1934
Study 14607206 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine SR
Number of subjects: 1934
Study 10544625 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mSRT (20‐m progressive shuttle run test)
Number of subjects: 1317
Study 10544625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb injury
Number of subjects: 1317
Study 8686973 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (low-dose lamivudine group)
Number of subjects: 254
Study 8686973 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine twice daily plus 200 mg of zidovudine three times daily (high-dose lamivudine group)
Number of subjects: 254
Study 8686973 — intervention group
Group type: COMPARATOR
Intervention: 0.75 mg of zalcitabine plus 200 mg of zidovudine three times daily (zalcitabine group)
Number of subjects: 254
Study 8686973 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of lamivudine plus zidovudine
Number of subjects: 254
Study 8686973 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine plus zidovudine
Number of subjects: 254
Study 8686973 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 254
Study 2051759 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related injuries in manufacturing industries and agriculture/forestry/fishing
Number of subjects: 0
Study 2051759 — intervention group
Group type: EXPERIMENTAL
Intervention: Service sector workers
Number of subjects: 0
Study 2051759 — intervention group
Group type: EXPERIMENTAL
Intervention: Food and fish processing industry
Number of subjects: 0
Study 2051759 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical engineering industry
Number of subjects: 0
Study 6337710 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine
Number of subjects: 609
Study 6337710 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 609
Study 6337710 — intervention group
Group type: EXPERIMENTAL
Intervention: BCNU plus high-dose methylprednisolone
Number of subjects: 609
Study 6337710 — intervention group
Group type: COMPARATOR
Intervention: High-dose methylprednisolone
Number of subjects: 609
Study 31851710 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique 1 (TFT1)
Number of subjects: 50
Study 31851710 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique 2 (TFT2)
Number of subjects: 50
Study 31851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinch technique 1 (PT1)
Number of subjects: 50
Study 31851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinch technique 2 (PT2)
Number of subjects: 50
Study 31851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate-assisted technique (PAT)
Number of subjects: 50
Study 31851710 — intervention group
Group type: COMPARATOR
Intervention: TFT2
Number of subjects: 50
Study 31851710 — intervention group
Group type: EXPERIMENTAL
Intervention: PT1
Number of subjects: 50
Study 31851710 — intervention group
Group type: COMPARATOR
Intervention: TFT1
Number of subjects: 50
Study 31851710 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT
Number of subjects: 50
Study 31851710 — intervention group
Group type: EXPERIMENTAL
Intervention: PT2
Number of subjects: 50
Study 29216820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 0.2 μg·kg-1·hr-1
Number of subjects: 49
Study 29216820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 0.5 μg·kg-1·hr-1
Number of subjects: 49
Study 29216820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion at 0.8 μg·kg-1·hr-1
Number of subjects: 49
Study 29216820 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (0.2, 0.5, 0.8 μg·kg-1·hr-1)
Number of subjects: 49
Study 29216820 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infusion of sufentanil
Number of subjects: 49
Study 26719230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg) added to 500 mg/m² pemetrexed and 75 mg/m² cisplatin (PCB)
Number of subjects: 448
Study 26719230 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed (PC)
Number of subjects: 448
Study 24995954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 34
Study 24995954 — intervention group
Group type: EXPERIMENTAL
Intervention: Butamirate (various doses)
Number of subjects: 34
Study 24995954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 22747949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program at the workplace including integrated care and participatory workplace intervention
Number of subjects: 0
Study 22747949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program at the workplace
Number of subjects: 0
Study 22747949 — intervention group
Group type: COMPARATOR
Intervention: Usual care by rheumatologist (Control)
Number of subjects: 0
Study 19318954 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 4 months
Number of subjects: 16
Study 19318954 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls (8 subjects)
Number of subjects: 16
Study 18332267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg for 10 minutes, followed by 2 mg/kg 15 minutes later if AF was not terminated)
Number of subjects: 336
Study 18332267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 336
Study 18332267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 16116152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem-cell rescue
Number of subjects: 560
Study 16116152 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (for infants)
Number of subjects: 560
Study 16116152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy
Number of subjects: 560
Study 12100793 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare (n=27)
Number of subjects: 43
Study 12100793 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n=16)
Number of subjects: 43
Study 10366368 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 2
Study 10366368 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 2
Study 7495598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered survey about risk factors for HIV infection
Number of subjects: 1030
Study 2249115 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin hydrochloride (3 mg)
Number of subjects: 53
Study 2249115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 7357798 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa, 1,000 mg
Number of subjects: 7
Study 7357798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7357798 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa, 1,000 mg and Metoclopramide, 10 mg
Number of subjects: 7
Study 30321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) at 10 °C for 10 minutes
Number of subjects: 22
Study 30321486 — intervention group
Group type: COMPARATOR
Intervention: Control (CON: 30 min seated)
Number of subjects: 22
Study 27784824 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 378
Study 27784824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 25402618 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (17 calls over 12 months)
Number of subjects: 115
Study 24628624 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method of uvular repair
Number of subjects: 60
Study 24628624 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of uvular repair
Number of subjects: 60